Monitoring Heparin Therapy Using Activated Partial Thromboplastin Time – Results of a Multicenter Trial Establishing the Therapeutic Range for SILIMAT, a Reagent with High Sensitivity to Heparin

Pierre Toulon; Brigitte Boutière; Marie-Hélène Horellou; Marie Christine Trzeciak; Meyer M. Samama

doi:10.1055/s-0037-1615147

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(01): 104-108
DOI: 10.1055/s-0037-1615147

Rapid Communication

Schattauer GmbH

Monitoring Heparin Therapy Using Activated Partial Thromboplastin Time – Results of a Multicenter Trial Establishing the Therapeutic Range for SILIMAT, a Reagent with High Sensitivity to Heparin

Pierre Toulon

¹Laboratoires d’Hématologie, Hôpital Cochin, Paris

,

Brigitte Boutière

²Hôpital de la Conception, Marseille

,

Marie-Hélène Horellou

³Hôtel Dieu de Paris

,

Marie Christine Trzeciak

⁴Hôpital Edouard Herriot, Lyon, France

,

Meyer M. Samama

³Hôtel Dieu de Paris

› Author Affiliations

Abstract

Summary

APTT is widely used for laboratory monitoring of treatment with unfractionated heparin (UFH). However, since its sensitivity to heparin varies significantly from one reagent to another, the therapeutic range had to be defined for each brand of APTT reagent. As an example, SILIMAT (bio-Mérieux) is a new APTT reagent containing rabbit brain phospholipids and micronized silica as an activator. Since its high sensitivity to heparin has been previously reported, a multicenter trial was carried out in an attempt to define the therapeutic range of APTT performed using this new reagent. For that purpose, 170 blood samples drawn for routine coagulation testing from 170 different patients treated with UFH were analyzed. A single batch of two different APTT reagents were used on KC10 coagulometers: SILIMAT and Automated APTT (Organon-Teknika) whereas the anti-Xa activity was evaluated by a chromogenic substrate-based assay. The same methodology was used in all the centers. In order to obtain a plasma anti-Xa activity within the therapeutic range i.e. between 0.30 and 0.70 IU/ml, the APTT ratios were found between 1.90 and 5.40 for SILIMAT, which corresponded to clotting times of the patients plasma between 63 and 178 s. The APTT ratios were significantly lower when evaluated using Automated APTT (between 1.70 and 4.10), with clotting times between 53 and 127 s. In addition, a good correlation was found between the Anti-Xa activity and APTT for both reagents (r >0.65). However, it is not possible to make recommendations regarding the therapeutic ranges without restrictions. Although about 70% of the patients with an anti-Xa activity between 0.30 and 0.70 IU/ml had an APTT in the above defined ranges, the degree of concordance between the two assays is not absolute. Actually more than 30% of the patients had discordant anti-Xa activity and APTT and more than a quarter of the patients included in the above defined therapeutic range for APTT had an anti-Xa activity outside the 0.30-0.70 IU/ml range, whatever the reagent used. In conclusion, to define the therapeutic ranges of APTT using the recommended method is practicable but some critical points could be raised, suggesting that a better method is awaited in order to improve the standardization.

Full Text

References

References
1 Barritt DW, Jordon SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; I: 1309-12.
2 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
3 Hirsh J, van Aken WG, Gallus AS, Dollerey CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-5.
4 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
5 Levine MN, Raskob G, Landerfeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatments. Chest 1995; 108 (Suppl.) 276S-90S.
6 Hull RD, Raskob GE, Rosenbloom D, Panjuu AA, Brill-Edwards P, Ginsberg JS. et al. Heparin for 5 days as compared to 10 days in the treatment of proximal deep vein thrombosis. N Engl J Med 1990; 322: 1260-4.
7 Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
8 Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108 (Suppl.) 258S-75S.
9 Specto I, Corn M. Control of heparin therapy with activated partial thromboplastin times. JAMA 1967; 201: 75-7.
10 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
11 Gawoski JM, Arkin CF, Bovill T, Brandt JT, Rock Jr WA, Triplett DA. The effect of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects. Arch Pathol Lab Med 1987; 111: 785-90.
12 Poller L, Thompson JM, Taberner DA. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions. Res Clin Lab 1989; 19: 363-70.
13 Lentz SR. Disorders of hemostasis-thromboembolic disorders. In: Woodley M, Whelan A. eds. Manual of medical therapeutics. 27th edition. Little, Brown; 1992. pp 323-40.
14 Moser KM. Pulmonary thromboembolism. In: Wilson JD, Braunwald E, Isselbacher KT, Petersdorf RG, Martin JB, Fauci AS, Root RK. eds. Harrison’s principles of internal medicine. 12th edition. McGraw-Hill; 1991. pp 1090-6.
15 Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992; 102 (Suppl.) 337S-51S.
16 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994; 89: 1449-68.
17 Groupe d’Etude sur l’Hémostase et la Thrombose. Recommandations: utilisation des héparines en pratique médicale courante. Sang Thrombose Vaisseaux (Paris) 1996; 8 (Suppl.) 5-13.
18 Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time – a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol 1980; 74: 668-73.
19 Brandt JT, Triplett DA. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 1981; 76 (Suppl.) 530-7.
20 Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma. Am J Clin Pathol 1990; 93: 684-9.
21 Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Comparison of ex-vivo measurement and in vitro standardization. Am J Clin Pathol 1985; 84: 351-4.
22 Van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationship between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23.
23 Brill-Edwards P, Ginsburg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
24 van den Besselaar AMHP, Meeuwisse-Braun J, Strebus A, Schaeffer-van Mansfeld H, Witteveen E, van der Meer FJM. Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometer. Thromb Haemost 1995; 74: 1383-4.
25 Van der Velde EA, Poller L. The APTT monitoring of heparin – the ISTH/ICSH collaborative study. Thromb Haemost 1995; 73: 73-81.
26 Trzeciak MC, Hanss M, Bonvarlet MN, Dechavanne M. Sensitivity of a new reagent Silimat^® (bioMérieux) for the activated partial thromboplastin time determination. Thromb Haemost 1991; 65: 1321 (abstr).
27 Wessler S, Morris LE, Ho C, Moran J. Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis. Circulation 1955; XII: 553-6.
28 Zucker S, Cathey MH, Wylie RL. Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effect of heparin. J Lab Clin Med 1969; 73: 320-6.
29 Spector I, Corn M. Control of heparin therapy with activated partial thromboplastin times. JAMA 1967; 201: 75-7.
30 Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B. et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95.
31 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and the antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-84.
32 Wester JPJ, de Walk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen HK, Hart HC, Sixma JJ. Risk factors for bleeding during treatment of acute venous thrombosis. Thromb Haemost 1996; 76: 682-8.
33 Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated thromboplastin time reagents produced by the same manufacturer. Am J Clin Pathol 1988; 89: 19-23.
34 D’Angelo A, Seveso MP, D’Angelo SV. et al. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297-306.
35 Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107: 105-10.
36 Kitchen S, Theaker J, Phillips JK, Preston FE. Comparison of anti-Xa assays and the heparin assay by protamine titration during unfractionated heparin therapy. Br J Haematol 1997; 97 (Suppl. 01) 77 (abstract).
37 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl.) 231S-46S.